Can-Fite BioPharma announced the Company’s oncology drug candidate, Namodenoson, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration, FDA, for the indication of pancreatic cancer, one of the most aggressive malignancies. The designation as an orphan drug will provide among others, potential for market exclusivity for seven years after approval and several and regulatory advantages
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma treatment of pancreatic cancer granted FDA orphan status
- Can-Fite BioPharma’s Lucrative Veterinary Licensing Deal
- Can-Fite BioPharma signs development, commercialization agreement with Vetbiolix
- Can-Fite Advances Pancreatic Cancer Drug Trial
- Can-Fite received approval from Israeli MoH to conduct Phase IIa trial